Headache News and Research

Latest Headache News and Research

Shire announces data from a 12-month study of Daytrana for ADHD

Shire plc has announced that data from a 12-month study of DAYTRANATM (methylphenidate transdermal system), the Attention Deficit Hyperactivity Disorder (ADHD) patch, demonstrated that DAYTRANA provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years.

28 Oct 2007

Sanofi Pasteur receives FDA approval of Menactra meningococcal vaccine for children

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has granted licensure to expand the indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include children 2 years through 10 years of age.

22 Oct 2007

Mayo Clinic clarifies diagnosis for primary central nervous system vasculitis (PCNSV)

Mayo Clinic has clarified the methods of diagnosis and optimal management of a rare and little-understood blood vessel disease of the brain and spinal cord that often leads to stroke or death.

19 Oct 2007

FDA approves doripenem injection to treat complicated urinary tract and intra-abdominal infections

The U.S. Food and Drug Administration has approved doripenem injection, 500 mg intravenous infusion, for the treatment of complicated urinary tract and intra-abdominal infections.

19 Oct 2007

FDA approves raltegravir new HIV drug

The U.S. Food and Drug Administration (FDA) has approved raltegravir tablets for treatment of Human Immunodeficiency Virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents.

17 Oct 2007

Modafinil effective treatment for excessive sleepiness

A study published in the October 15 issue of the Journal of Clinical Sleep Medicine (JCSM) finds that modafinil is well-tolerated in the treatment of excessive sleepiness associated with disorders of sleep and wakefulness such as shift work sleep disorder, obstructive sleep apnea (OSA) and narcolepsy, and does not affect cardiovascular or sleep parameters.

16 Oct 2007

Once-a-day epilepsy drug lamotrigine effective for partial seizures

The epilepsy drug lamotrigine is effective in controlling partial seizures when taken once a day as an added therapy, according to a study published in the October 16, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.

16 Oct 2007

New analyses of long-term LIALDA (mesalamine) data presented at ACG

Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.

16 Oct 2007

Anesthesia passport ensures optimal care

A patient “passport,” outlining individual anesthetic experiences and side effects, can help patients to better understand the procedures they have undergone in the operating room and potentially avoid future, unnecessary complications.

15 Oct 2007

Central nervous system infections after heart transplants

Central nervous system infections develop infrequently following heart transplants but are a significant predictor of death, according to an article posted online today that will appear in the December 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Oct 2007

Brain eating amoeba in lake kills sixth victim

A Texas boy has become the sixth person this summer to die from brain eating amoeba.

7 Oct 2007

FDA approves Afluria in time for flu season

The U.S. Food and Drug Administration today approved Afluria, an additional seasonal influenza vaccine for the immunization of people ages 18 and older.

29 Sep 2007

Survival data presented from phase II study of hormone-resistant prostate cancer patients

The results from the randomized, double -blind, placebo -controlled, Phase II EPOC (Endothelin A Proof Of Concept) Study of ZD4054 - a specific endothelin A (ETA) receptor antagonist – were delivered at the 14th European Congress of Clinical Oncology (ECCO, 23-27 September, Barcelona).

26 Sep 2007

New AstraZeneca compound shows promoise for hormone resistant prostate cancer patients with bone metastases

New Phase II data suggests that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.

26 Sep 2007

New Pfizer HIV drug approved for sale in Europe

Drug giant Pfizer has been given approval for it's new HIV drug Celsentri to go on sale in Europe.

24 Sep 2007

FDA warns consumers not to consume Organic Pastures raw cream

The U.S. Food and Drug Administration (FDA) is warning consumers not to drink or consume raw (unpasteurized) cream labeled as "ORGANIC PASTURES Grade A RAW CREAM" in one-pint plastic bottles coded "SEP 14" through "SEP 21."

24 Sep 2007

FDA accepts Sucampo's sNDA for Lubiprostone for the treatment of irritable bowel syndrome

Sucampo Pharmaceuticals, Inc., has announced that the supplemental New Drug Application (sNDA) for lubiprostone (8 mcg, oral gel capsules, twice daily) for the treatment of irritable bowel syndrome with constipation (IBS-C) has been accepted for review by the U.S. Food and Drug Administration (FDA).

18 Sep 2007

Ticks abound both sides of the Atlantic

Ticks are making their presence felt both sides of the Atlantic. The British public is being warned to take precautions against ticks following a rise in the tick population after a wet and mild summer

17 Sep 2007

Breast reductions of less than 500 grams per breast greatly ease women's pain

Smaller-framed women reap significant health and quality-of-life benefits from breast reductions that involve the removal of under 500 grams of tissue per breast, according to a first-of-its-kind study from NewYork-Presbyterian Hospital/Weill Cornell Medical Center and the New York University School of Medicine.

17 Sep 2007